StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)

Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –

Exelixis enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Exelixis's enterprise value was $16.76B on Nov 11, 2026, against $10.85B a year earlier. Over the last 5 years it ranged from $3.50B to $16.76B, with a median of $6.19B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$16.76B+55.7%
2025Dec 31, 2025$10.76B+29.2%
2024Dec 31, 2024$8.33B+31.0%
2023Dec 29, 2023$6.36B+75.4%
2022Dec 30, 2022$3.63B-16.6%
2021Dec 31, 2021$4.35B-13.4%
2020Dec 31, 2020$5.02B+9.4%
2019Dec 31, 2019$4.59B-12.5%
2018Dec 31, 2018$5.24B-39.2%
2017Dec 29, 2017$8.62B+107.1%
2016Dec 30, 2016$4.16B+186.0%
2015Dec 31, 2015$1.46B+227.6%
2014Dec 31, 2014$444.27M-62.7%
2013Dec 31, 2013$1.19B+165.3%
2012Dec 31, 2012$449.08M-49.4%
2011Jul 29, 2011$887.31M+12.0%
2010Dec 31, 2010$792.27M–

More Exelixis figures

See a number that looks wrong?